Form D · Biotechnology
Addition Therapeutics, Inc.
South San Francisco, CA · CIK 0002102340
Offering snapshot reported Dec 22, 2025 · SEC filing
- Reported sold
- $28M Offering amount: $28M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 11, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2025 | Initial | $28,000,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-567798
Source: Form D, filed Dec 22, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Bisgaard | Director |
| Kathleen Collins | Director |
| Lawrence Kong | Executive |
| Jennifer Lee | Director |
| Ronald Park | Director, Executive |
| Matthew Patterson | Director |
| Jayson Punwani | Director |
| Laetitia Schwab | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 Haskins Way, Suite 300
South San Francisco, CA, 94080
South San Francisco, CA, 94080